Baylor College of Medicine and MVision AI Collaborate to Drive AI-Powered Innovations in Radiation Therapy

Helsinki, Finland, October 11, 2024 – Baylor College of Medicine and MVision AI have entered into a strategic research and development agreement to drive innovation in radiation therapy through AI technology. This collaboration aims to accelerate the clinical adoption of AI-powered solutions, enhancing the efficiency and effectiveness of cancer treatment.

Baylor College of Medicine, a world-renowned institution, is at the forefront of medical research, clinical practice, and education. Its Department of Radiation Oncology, led by Drs Daniel Hamstra and Baozhou Sun, is known for pioneering advancements in radiotherapy, dedicated to improving patient outcomes through innovative treatment methods and cutting-edge technologies.

MVision AI, a leading provider of AI-powered, cloud-based solutions for radiation therapy, is transforming cancer care with its automation tools. The company’s mission is to streamline the treatment planning process, reduce clinician workload, and deliver faster, more precise care. With a presence in over in 20+ countries globally, MVision AI is shaping the future of radiation oncology through its innovative technology.

This collaboration combines their strengths: the radiotherapy clinical know-how with the expertise on AI based algorithms. Together, Baylor and MVision AI will focus on developing new AI models and workflows designed to support radiation therapy professionals. These advancements are set to improve both the speed and consistency of treatment, with the goal of achieving “same-day treatment” for all cancer patients. 

“We are thrilled to collaborate with Baylor College of Medicine,” said Dharani Rangaraj, Chief Executive Officer of MVision AI. “The synergy from our respective strengths in AI and clinical practice creates unique opportunities to develop meaningful solutions in radiation therapy. Our shared commitment is to deliver practical, trustworthy AI-powered tools that support oncology teams in their daily work, ultimately benefiting both radiation therapy professionals and patients through improved efficiency and quality of care.”

Greg Brown, Vice President of Sales for the Americas at MVision AI, highlighted the impact of the collaboration: “Working with a prestigious institution like Baylor allows us to push the boundaries of what’s possible in radiation therapy. Together, we’re setting a new standard for how AI can enhance patient care, making treatment faster, more consistent, and accessible.”

Dr. Daniel Hamstra, Chair of the Department of Radiation Oncology at Baylor College of Medicine: “We are excited to work with MVision AI to improve cutting-edge AI technology and advance the AI application in radiation oncology. This collaboration will enable us to enhance the precision and efficiency of our treatments, ultimately improving patient outcomes and setting new standards in cancer care.”

Dr. Baozhou Sun, Director of Medical Physics in the Department of Radiation Oncology at Baylor College of Medicine: “Integrating MVision AI’s advanced solutions with clinical expertise represents a significant step forward in radiation therapy. Together, we aim to develop innovative workflows that not only streamline the treatment process but also ensure that our patients receive the highest quality of care in a timely manner.”

For more information on this partnership, contact us at info@mvision.ai.

Our Newsletter

Subscribe to get information, latest news and other interesting offers about MVision AI

Related Posts

26.8.2024

Lung Cancer Awareness–Examining Tobacco’s Effect

As August comes to a close, we take a moment to reflect on World Lung Cancer Day, observed earlier this month. This year’s focus has underscored the critical fact that tobacco smoking remains the leading cause of lung cancer. Understanding this connection is essential for both prevention and treatment, emphasizing…

News

6.8.2024

MVision AI Secures CDSCO Approval to Revolutionize Cancer Treatment Planning in India

HELSINKI, Finland – August, 2024 MVision AI is excited to announce that our application for MVision AI Segmentation (Contour+) has been approved by the Central Drugs Standard Control Organization (CDSCO) under the “Image Segmentation Application Software” category. This approval facilitates the deployment of our advanced image analysis algorithms in radiation…

Press Releases

2.7.2024

Breaking New Ground: MVision AI Contour+ for Upright MRI Scans

Results on testing MVision AI Contour+ for an ingenious and modern approach in radiation therapy have been recently presented at the 62nd Particle Therapy Co-Operative Group (PTCOG) conference in Singapore. Despite being trained using supine MR data and a different magnetic strength from different scanners, authors reported that MVision AI's…

Articles